We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,093

Did You Unintentionally Just Settle? A Cautionary Reminder to be Objectively Clear in Your Negotiations
  • Bereskin & Parr LLP
  • Canada
  • August 10 2018

The Federal Court recently found that parties to a patent infringement action settled the litigation, and enforced an agreement, despite an ongoing


The Biosimilar Landscape in Canada
  • Bereskin & Parr LLP
  • Canada
  • August 9 2018

Biologics are drugs which contain an active medicinal ingredient that is derived from living organisms or their cells. They are generally larger and


Health Canada issues updated guidance on PMNOC Regulations
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 8 2018

Health Canada recently issued updated guidance on the Patented Medicines (Notice of Compliance) (PMNOC) Regulations. Revisions include the


IP Q&A: How to Navigate Canada's Official Marks System
  • Blake Cassels & Graydon LLP
  • Canada
  • August 3 2018

Running parallel to Canada's trademark system is another regime for "official marks". The official mark regime is exclusive to public authorities such


A Lesson on When to Strike: Case Comment on Badawy v 1038482 Alberta Ltd et al., 2018 FC 807
  • McCarthy Tétrault LLP
  • Canada
  • August 3 2018

In a Federal Court decision released on July 31, 2018, Badawy v 1038482 Alberta Ltd et al, a claim for infringement of intellectual property was


Quebec court declines to dismiss claim under Ontario Statute of Monopolies
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • August 1 2018

In an action relating to amlodipine besylate (Pfizer's NORVASC), Apotex is seeking relief in the Quebec Superior Court pursuant to: the Ontario


Rx IP Update - July 2018
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 31 2018

As previously reported (here and here), the Patented Medicine Prices Review Board (PMPRB) has been consulting on its proposed reform of the federal


Shire’s VYVANSE patent valid, prohibition order issued
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 27 2018

On June 29, 2018, Justice Fothergill of the Federal Court granted Shire’s application under the pre-amended Patented Medicines (Notice of Compliance


FCA Affirms Patent Application is “Dead” Following Failure to Respond to Requisition
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • July 24 2018

Under rigid rules governing the patent prosecution process in Canada, adhering to strict deadlines is crucial for prospective patentees. In this


It’s Settled Then: Federal Court Enforces Settlement where Parties Disagreed on Terms of Formal Settlement Agreement
  • McCarthy Tétrault LLP
  • Canada
  • July 17 2018

The Federal Court’s recent decision in Maoz Betser-Zilevitch v Nexen Inc. et. al., 2018 FC 735 is a reminder to litigants that “a settlement agreement